2022
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Nardone A, Qiu X, Spisak S, Nagy Z, Feiglin A, Feit A, Cohen Feit G, Xie Y, Font-Tello A, Guarducci C, Hermida-Prado F, Syamala S, Lim K, Munoz Gomez M, Pun M, Cornwell M, Liu W, Ors A, Mohammed H, Cejas P, Brock JB, Freedman ML, Winer EP, Fu X, Schiff R, Long HW, Metzger Filho O, Jeselsohn R. A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Research 2022, 82: 3673-3686. PMID: 35950920, PMCID: PMC9588703, DOI: 10.1158/0008-5472.can-21-3186.Peer-Reviewed Original ResearchConceptsInvasive lobular breast cancerInvasive ductal cancerLobular breast cancerTamoxifen resistanceBreast cancerInferior long-term outcomesTumor progressionLong-term outcomesBreast cancer subtypesPotential therapeutic avenuesDuctal cancerClinical findingsPoor outcomeReceptor axisClinical trialsDisease progressionPatient outcomesPreclinical modelsClinical investigationRelated commentaryTherapeutic avenuesCancer subtypesTherapeutic resistanceCancerClinical samples
2021
Association of pathological complete response rates and TILs in triple-negative breast cancer patients.
Kassem M, Goldstein D, Schnell P, Grimm M, Quiroga D, Miah A, Vargo C, Shinde N, Michael B, Pariser A, Gatti-Mays M, VanDeusen J, Williams N, Stover D, Sardesai S, Wesolowski R, Lustberg M, Ramaswamy B, Tozbikian G, Cherian M. Association of pathological complete response rates and TILs in triple-negative breast cancer patients. Journal Of Clinical Oncology 2021, 39: e12596-e12596. DOI: 10.1200/jco.2021.39.15_suppl.e12596.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor-infiltrating lymphocytesInternational TILs Working GroupPathological complete response rateComplete response rateNeoadjuvant chemotherapyLong-term prognosisTNBC patientsBreast cancerAssociation of TILsResponse rateHigh distant recurrence rateOhio State University Comprehensive Cancer CenterTriple-negative breast cancer patientsSingle-institution retrospective analysisHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Residual cancer burden indexRates of breastDistant recurrence ratesPreoperative systemic therapyGrowth factor receptor 2Majority of patientsInvasive ductal cancerBreast cancer patients
2019
Molecular Breast Imaging in Patients with Suspicious Calcifications
Hunt K, Hruska C, Johnson M, Conners A, O’connor M, Rhodes D, Basappa S, Wahner-Roedler D. Molecular Breast Imaging in Patients with Suspicious Calcifications. Journal Of Breast Imaging 2019, 1: 303-309. PMID: 38424809, DOI: 10.1093/jbi/wbz054.Peer-Reviewed Original ResearchMolecular breast imagingSuspicious calcificationsNegative predictive valueTelluride gamma cameraPredictive valueMedian pathologic sizeInvasive ductal cancerOccult breast cancerInjection of TcAreas of calcificationBreast imagingNuclear medicine techniquesPrebiopsy settingGamma cameraBiopsy findingsDuctal cancerPathologic sizeIncidental lesionsDuctal carcinomaInvasive cancerAdditional biopsiesBreast cancerStereotactic biopsyBiopsyMolecular breastSurvival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
Sardesai S, Kassem M, Morgan E, Palettas M, Stephens J, Williams N, Stover D, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B. Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2019, 37: e12050-e12050. DOI: 10.1200/jco.2019.37.15_suppl.e12050.Peer-Reviewed Original ResearchDisease-free survivalPositive breast cancerHormone receptor expressionOverall survivalBreast cancerReceptor expressionPositive diseaseTumor gradeEarly-stage HER2-positive breast cancerOhio State University Comprehensive Cancer CenterSecond primary breast cancerSingle-institution retrospective analysisHER2-positive breast cancerAdjuvant ovarian suppressionHR-negative diseaseHR-negative patientsHR-positive diseaseTriple-positive diseaseAnti-estrogen therapyComplete pathologic responseSingle institution experienceKaplan-Meier methodPrimary breast cancerInvasive ductal cancerLow tumor gradeCLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience
Boutrid H, Lustberg M, Vandeusen J, Sardesai S, Stover D, Wesolowski R, Cherian M, Stephens J, Palettas M, Morgan E, Kassem M, Berger M, Vargo C, Ramaswamy B, Williams N. CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience. Journal Of The National Comprehensive Cancer Network 2019, 17: clo19-027. DOI: 10.6004/jnccn.2018.7251.Peer-Reviewed Original ResearchMetastatic invasive lobular carcinomaProgression-free survivalInvasive lobular carcinomaFirst-line treatment groupEndocrine therapyFirst-line treatmentOverall survivalCDK 4/6 inhibitorsMetastatic settingBone metastasesTreatment groupsMedian progression-free survivalOhio State University Comprehensive Cancer CenterInvasive breast cancer casesOnly bone metastasesMedian overall survivalFirst-line therapyWidespread metastatic diseaseKaplan-Meier methodRetrospective chart reviewSingle institution experienceInvasive ductal cancerKaplan-Meier curvesPreferred treatment optionAppropriate clinical context
2012
Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
Greenup R, Camp M, Taghian A, Buckley J, Coopey S, Gadd M, Hughes K, Specht M, Smith B. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals Of Surgical Oncology 2012, 19: 3275-3281. PMID: 22851048, DOI: 10.1245/s10434-012-2546-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCombined Modality TherapyCosts and Cost AnalysisFemaleFollow-Up StudiesHealth Care CostsHumansMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm InvasivenessPrognosisRetrospective StudiesConceptsWhole breast radiation therapyBreast cancerRT optionsExternal-beam partial breast irradiationLeukemia Group B 9343MethodsAn institutional review boardResultsMedian patient ageCurrent Procedural Terminology codesMedian tumor sizeInvasive ductal cancerSitu breast cancerPartial breast irradiationProcedural Terminology codesRadiation treatment optionsInstitutional review boardC-RTBackgroundRadiation therapyRT regimensBreast conservationDuctal cancerLobular cancerMixed histologyPatient ageRetrospective reviewTumor histology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply